摘要:
The invention relates to zinc amide bases of general formula (R1R2N)2-Zn • aMgX12 • bLiX2, wherein R1 and R2 are each independently selected from substituted or unsubstituted, linear or branched alkyl, alkenyl, alkinyl or silyl derivatives thereof, and substituted or unsubstituted aryl or heteroaryl. R1and R2 can form together a ring structure, or R1 and/or R2 can be part of a polymer structure; X12 is a divalent anion or two monovalent anions that are independent from each other; X2 is a monovalent anion; a > 0; and b > 0. Said zinc- amide bases can be used, amongst other things, for deprotonation and for the metallization of aromates.
摘要翻译:本发明涉及通式(R 1 R 2 N)2 -Zn·aMgX 12·bLiX 2的锌酰胺碱,其中R 1和R 2各自独立地选自取代或未取代的直链或支链烷基,链烯基,炔基或甲硅烷基衍生物, 未取代的芳基或杂芳基。 R 1和R 2可以一起形成环结构,或者R 1和/或R 2可以是聚合物结构的一部分; X12是二价阴离子或两个彼此独立的单价阴离子; X2是单价阴离子; a> 0; 所述锌 - 酰胺碱可以用于去质子化和用于金属化的芳族化合物。
摘要:
Disclosed are substituted 7-membered to 12-membered cycloalkanes comprising terminal groups, especially chloride atoms, on tertiary ring carbon atoms, a method for the production thereof, and the use thereof as cationic polymerization initiators, particularly for cationically polymerizing isobutene. Preferred compounds are 1,4-dichloro-1,4-dimethylcyclooctane, 1,5-dichloro-1,5-dimethylcyclooctane, and mixtures thereof. Said compounds are produced by adding hydrocarbon to adequately substituted cycloalkapolyenes.
摘要:
The present application relates to mixed Mg/Li amides of the general formula R1R2N-Mg-NR3R4.zLiY (II) wherein R1, R2, R3, and R4 are, independently, selected from H, substituted or unsubstituted aryl or heteroaryl containing one or more heteroatoms, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or silyl derivatives thereof; and R1 and R2 together, or R3 and R4 together can be part of a cyclic or polymeric structure; and wherein at least one of R1 and R2 and at least one of R3 and R4 is other than H; Y is selected from the group consisting of F; Cl; Br; I; CN; SCN; NCO; HaIOn, wherein n = 3 or 4 and Hal is selected from Ci, Br and I; NO3; BF4; PF6; H; a carboxylate of the general formula RxCO2; an alcoholate of the general formula ORx; a thiolate of the general formula SRx; RxP(O)O2; or SCORx; or SCSRx; OnSRx, wherein n = 2 or 3; or NOn, wherein n = 2 or 3; and a derivative thereof; wherein Rx is a substituted or unsubstituted aryl or heteroaryl containing one or more heteroatoms, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or derivatives thereof, or H; m is O or 1; and z > 1; as well as a process for the preparation of the mixed Mg/Li amides and the use of these amides, e.g. as bases.
摘要:
The present invention relates to a method and an apparatus for a fast thermo-optical characterisation of particles. In particular, the present invention relates to a method and a device to measure the stability of (bio)molecules, the interaction of molecules, in particular biomolecules, with, e.g. further (bio)molecules, particularly modified (bio)molecules, particles, beads, and/or the determination of the length/size (e.g. hydrodynamic radius) of individual (bio)molecules, particles, beads and/or the determination of length/size (e.g. hydrodynamic radius).
摘要:
The present invention relates to transgenic pigs containing a dominant-negative incretin hormone receptor, namely the dominant-negative human glucose-dependent insulinotropic polypeptide receptor. The present invention furthermore relates to uses of these transgenic pigs as clinically relevant animal model systems for studying the pathogenesis and novel therapies for diabetes mellitus type 2, particularly for the maintenance and expansion of pancreatic β-cell mass.
摘要:
The present application relates to mixed Mg/Li amides of the general formula R1R2N-Mg(NR3R4)mX,.m zLiY (II) wherein R1, R2, R3, and R4 are, independently, selected from H, substituted or unsubstituted aryl or heteroaryl containing one or more heteroatoms, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or silyl derivatives thereof; and R1 and R2 together, or R3 and R4 together can be part of a cyclic or polymeric structure; and wherein at least one of R1 and R2 and at least one of R3 and R is other than H; X and Y are, independently, selected from the group consisting of F; Cl; Br; I; CN; SCN; NCO; HaIOn , wherein n = 3 or 4 and Hal is selected from Cl, Br and I; NO3; BF4; PF6; H; a carboxylate of the general formula RXCO2; an alcoholate of the general formula ORX; a thiolate of the general formula SRX; RXP(O)O2; or SCORX; or SCSRX; OnSRx, wherein n = 2 or 3; or NOn, wherein n = 2 or 3; and a derivative thereof; wherein Rx is a substituted or unsubstituted aryl or heteroaryl containing one or more heteroatoms, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or derivatives thereof, or H; m is O or 1 ; and z > O; as well as a process for the preparation of the mixed Mg/Li amides and the use of these amides, e.g. as bases.
摘要:
The present invention refers to a pharmaceutical preparation for treating inflammatory diseases and microbial infections comprising a pharmaceutically effective amount of ozone and at least one amino acid, or at least one ozonized amino acid. Also described is the use of a preparation as described before for providing a medicament for treating inflammatory diseases, microbial infections and for immune modulation. The pharmaceutical preparation according to the invention is particularly useful in the treatment of oral inflammations.
摘要:
The present invention refers to novel conjugate molecules and their use or the transport of nano- and macromolecular structures into cells and/or the nucleus. More particularly, the present invention refers to conjugate molecules containing a carrier, preferably thiopyridyl moieties, and a cargo moiety. Thereby, the thiopyridyl moiety is bound to the cargo moiety to act as a carrier, particularly for efficient intracellular and/or intranuclear delivery of drugs, nano-or macromolecular structures, etc.. The novel conjugate molecules are provided for the manufacture of a medicament for gene therapy, apoptosis, or for the treatment of diseases such as cancer, autoimmune diseases or infectious diseases.
摘要:
The present invention relates to a method of generating a detectable protein capable of binding an antigen of interest, comprising the steps of: (a) obtaining from an antibody producing cell of Camelidae or a pool of such cells, a first nucleic acid molecule or a pool of such nucleic acid molecules, encoding the variable region of an immunoglobulin or recombinantly or (semi)synthetically producing such first nucleic acid molecule or pool of first nucleic acid molecules; (b) optionally selecting from said pool a particular nucleic acid molecule encoding the variable region of a specific immunoglobulin; (c) fusing the coding region of the first nucleic acid molecule, encoding the variable region of an immunoglobulin in frame to the coding region of a second nucleic acid molecule, encoding a detectable marker (poly)peptide, wherein the coding region of the first nucleic acid molecule is located 5' of the coding region of the second nucleic acid molecule and wherein the coding regions are optionally separated by a coding region encoding a linker of at least one amino acid residue; and (d) expressing the fused nucleic acid molecule encoding the fusion protein in a cell or cell free extract. Furthermore, the present invention relates to a method for generating a library of detectable proteins capable of antigen binding and to a library generated by the methods of the present invention. Finally, the present invention also relates to a fusion protein comprising a first (poly)peptide sequence comprising the variable region of a heavy chain antibody of Camelidae and a second (poly)peptide sequence derivable from a fluorescent or chromophoric protein, wherein said (a) first (poly)peptide sequence is composed of framework 1, CDR1, framework 2, CDR2, framework 3 and CDR3, encoded by the nucleic acid sequence of SEQ ID NO: 2 or encoded by a nucleic acid sequence with at least 70% sequence identity or a fragment thereof; and (b) second (poly)peptide sequence is (i) the green fluorescent protein derivable from Aequorea victoria encoded by the nucleic acid sequence of SEQ ID NO: 7, or a fluorescent mutant or fragment thereof; (ii) the red fluorescent protein derivable from Discosoma (DsRed) encoded by the nucleic acid sequence of SEQ ID NO: 9, or a fluorescent mutant or fragment thereof; or (iii) a functional homologue of (i) or (ii) with at least 80% sequence identity, wherein said first (poly)peptide sequence is located N-terminally of said second (poly)peptide sequence, said sequences being optionally separated by a linker of at least one amino acid residues.
摘要翻译:本发明涉及产生能够结合感兴趣抗原的可检测蛋白质的方法,包括以下步骤:(a)从骆驼科的抗体产生细胞或这样的细胞池获得第一核酸分子或 编码免疫球蛋白的可变区或重组或(半)合成地产生第一核酸分子或第一核酸分子的池的这种核酸分子的集合; (b)任选地从所述池选择编码特定免疫球蛋白的可变区的特定核酸分子; (c)将编码可检测标记(多)肽的编码可检测标记(多)肽的第二核酸分子的编码区编码框架中的免疫球蛋白的可变区的第一核酸分子的编码区融合,其中第一 核酸分子位于第二核酸分子的编码区的5',并且其中编码区任选地由编码至少一个氨基酸残基的接头的编码区分离; 和(d)在细胞或无细胞提取物中表达编码融合蛋白的融合核酸分子。 此外,本发明涉及产生能够抗原结合的可检测蛋白质文库的方法和通过本发明的方法产生的文库。 最后,本发明还涉及包含第一(多)肽序列的融合蛋白,所述第一(多)肽序列包含骆驼科的重链抗体的可变区和可衍生自荧光或发色蛋白的第二(多)肽序列,其中所述( )第一(多)肽序列由由SEQ ID NO:2的核酸序列编码或由具有至少70%序列的核酸序列编码的框架1,CDR1,框架2,CDR2,框架3和CDR3组成 身份或其片段; 和(b)第二(多)肽序列是(i)可由SEQ ID NO:7的核酸序列编码的维他命水母的绿色荧光蛋白或荧光突变体或其片段; (ii)衍生自由SEQ ID NO:9的核酸序列编码的Discosoma(DsRed)的红色荧光蛋白或荧光突变体或其片段; 或(iii)具有至少80%序列同一性的(i)或(ii)的功能同系物,其中所述第一(多)肽序列位于所述第二(多)肽序列的N-末端,所述序列任选分离 通过至少一个氨基酸残基的接头。
摘要:
The present invention is related to a combination of at least a first nucleic acid molecule and at least a second nucleic acid molecule for the detection of and/or discrimination between bacteria of the group of coliforms and bacteria of the Escherichia coli genogroup, whereby the first nucleic acid and the second nucleic acid differ in their nucleic acid sequence and comprise fragments of the origin of replication ( oriC ) locus sequence of said bacteria.